回到治疗模式的基础

IF 101.8 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2025-04-16 DOI:10.1038/d41573-025-00072-4

Asher Mullard

引用次数: 0

摘要

武田的研发主管Andy Plump讨论了该公司不断发展的产品线、治疗方式以及生物技术、美国国立卫生研究院（NIH）和美国食品和药物管理局（FDA）的剧变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Back to therapeutic modality basics

查看原文本刊更多论文

Back to therapeutic modality basics

Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA. Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.